HealthTree Logo
search more_vert
App Logo
close
person Sign In / Create Account
A New Bi-Specific Antibody Therapy On The Horizon: ABBV-383
Posted: Jun 01, 2023
A New Bi-Specific Antibody Therapy On The Horizon: ABBV-383 image

HealthTree University: Therapies On The Horizon - ABBV-383

ABBV-383 is a promising drug that works as a bi-specific antibody designed to bring the immune system to cancer cells, specifically plasma cells. It's currently being studied in a phase one trial and has shown effectiveness at a recommended dose of 60 milligrams. Watch the video below for more information on how it works, its side effects, dosing, and administration. You can watch the whole course at HealthTree University.

ABBV-383

 

We’d like to thank our faculty who donated their time in creating these videos, including:

  • Marcella Kaddoura, MD
  • Muzaffar Qazilbash, MD

Want more?

We have over 500 HealthTree University videos online at HealthTree University! Learn the basics (and the not-so-basics) of myeloma from some of the top myeloma doctors in the world!

 

The author Cynthia Chmielewski

about the author
Cynthia Chmielewski

Cynthia (Cindy) Chmielewski is a professional educator and myeloma advocate. As a former teacher, she now teaches myeloma patients how to advocate for themselves as the Director of HealthTree University. You can follow her on Twitter @myelomateacher

Get the latest thought leadership on Multiple Myeloma delivered straight to your inbox.

Subscribe to the weekly "HealthTree Community for Multiple Myeloma Newsletter" for Multiple Myeloma news, life with Multiple Myeloma stories, Multiple Myeloma clinical trials, Multiple Myeloma 101 articles and events with Multiple Myeloma experts.

Thanks to our HealthTree Community for Multiple Myeloma Sponsors:

Janssen Oncology
Adaptive Biotechnologies
Amgen Oncology
Abbvie
Genentech
GSK
Bristol Myers Squibb

Follow Us

facebook instagram twitter youtube